Prospective, multicenter, randomized, open, uncontrolled clinical trial in relation (1: 1), of parallel groups, with subcutaneous immunotherapy in mixed polymerized presentation (100: 100), in patients with rhinoconjunctivitis sensitized to the following combination of pollen: Phleum Pratense and Olea Europaea and administered according to different guidelines
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ROXALL MEDICINA ESPAÑA, SA
- Phase: I
- Execution start: 29/07/2015
- End of execution: 30/06/2016
- IP: Mª ANGELES LARA JIMENEZ